FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/05/042447 [Registered on: 11/05/2022] Trial Registered Prospectively
Last Modified On: 11/07/2024
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Open Label 
Study Design  Single Arm Study 
Public Title of Study   A study to collect images from oral cavity of participating subjects to build an artificial intelligence-based tool for supporting the early detection of oral cancers. 
Scientific Title of Study   A prospective research study to collect images from oral cavity of participating subjects to build an artificial intelligence-based tool for supporting the early detection of oral cancers. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Unmesh Takalkar 
Designation  Chief Managing Director 
Affiliation  United CIIGMA Institute of Medical Sciences 
Address  United CIIGMA Institute of Medical Sciences Pvt. Ltd plot No.617 Survey No. 10, Shahanoorwadi, Dargah Road, Aurangabad- 431005, Maharashtra,India

Aurangabad
MAHARASHTRA
431005
India 
Phone  9822042425  
Fax    
Email  takalkar.unmesh@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Mr Ayan Neogi 
Designation  Managing Director 
Affiliation  Vivforever Aesthetics Private Limited 
Address  103 A, Bhairavi, Doordarshan CHS, Gokuldham, Goregaon East, Mumbai 400063, Maharashtra, India

Mumbai
MAHARASHTRA
400063
India 
Phone  9967968612  
Fax    
Email  ayanneogi@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Mr Ayan Neogi 
Designation  Managing Director 
Affiliation  Vivforever Aesthetics Private Limited 
Address  103 A, Bhairavi, Doordarshan CHS, Gokuldham, Goregaon East, Mumbai 400063, Maharashtra, India


MAHARASHTRA
400063
India 
Phone  9967968612  
Fax    
Email  ayanneogi@gmail.com  
 
Source of Monetary or Material Support  
Oraicle Biosciences Limited 
 
Primary Sponsor  
Name  Oraicle Biosciences Limited 
Address  Unit C, Anchor House, School Lane, Chandlers Ford, Eastleigh SO53 4DY, UNITED KINGDOM 
Type of Sponsor  Research institution 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 8  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Uma Datar  Bharati Vidyapeeth Medical College & Hospital,  Sangli – Miraj Road, Wanalesawadi, Sangli, Maharashtra – 416416,
Sangli
MAHARASHTRA 
9595624566

dataruv@gmail.com 
Dr Nitin Bhola  Datta Meghe Institute of Medical Sciences  Department of Head & Neck Cancers, Sawangi (Meghe), Wardha, Maharashtra 442004
Wardha
MAHARASHTRA 
9970070607

drnitinbhola@gmail.com 
Dr Rajnish Nagarkar  HCG Manavata Cancer Centre  Department of Oral Cancer & Clinical Research Unit , 1st Floor, Unit 2, Near Mylan Circle, Mumbai Naka, Nashik, Maharashtra 422002
Nashik
MAHARASHTRA 
9823061929

drraj@manavatacancercentre.com 
Dr Parag Watve  Kolhapur Cancer Centre Pvt Ltd  Head & Neck Cancer Department, A/p. R. S. No. 238, opp. Mayur Petrol Pump, Gokul Shirgaon, Maharashtra 416234
Kolhapur
MAHARASHTRA 
9823109918

paragwatve@gmail.com 
Dr M N Baruah  North East Cancer Prevention Centre  11th Mile, Jorabat, Guwahati-781023, Assam, India
Kamrup
ASSAM 
8486399973

munin_b@hotmail.com 
Dr Tanvy Subir Sansgiri  Pravara Institute Of Medical Science  Department of Oral & Maxillofacial Surgery, Loni, Taluka Rahata, District Ahmednagar 413736
Ahmadnagar
MAHARASHTRA 
9158209628

tanvy2192@gmail.com 
Dr Rajesh Padhy  Sparsh Hospital & Critical Care Pvt Ltd  Department of Oral Cancer, Plot No A/407 Sahidnagar, Bhubaneswar 751007
Khordha
ORISSA 
9437166120

drrajeshkumarpadhy@gmail.com 
Dr Unmesh Takalkar  United CIIGMA Institute of Medical Sciences Pvt Ltd  Department of Oral Cancer & Clinical Research Unit 6th Floor, Plot No.6/7 Survey No. 10, Shahnoorwadi, Dargah Road, Aurangabad- 431005, Maharashtra,India
Aurangabad
MAHARASHTRA 
9822042425

takalkar.unmesh@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 18  
Name of Committee  Approval Status 
Ethics Committee Group of CIIGMA Hospital  Approved 
Goenka Research Institute of Dental Science  Approved 
Health Point Ethics Committee Kolkata  Approved 
Health Point Ranchi Ethics Committee  Approved 
Institutional Ethical Committee Government Medical College Srinagar  Approved 
Institutional Ethics Committee Bharti Vidyapeeth Medical College & Hospital Sangli  Approved 
Institutional Ethics Committee Datta Meghe Institute of Medical Sciences  Approved 
Institutional Ethics Committee KIMS-ICON Hospital  Approved 
Institutional Ethics Committee of KLE Academy of Higher Education and Research  Approved 
Institutional Ethics Committee Rungta College of Dental Sciences and Research  Approved 
Institutional Ethics Committee Sparsh Hospital & Critical Care Pvt Ltd  Approved 
Kolhapur Cancer Centre Institutional Ethics Committee  Approved 
Lifepoint Research - Ethics Committee  Approved 
Manavata Clinical Research Institute Ethics Committee  Approved 
Pravara Institute of Medical Sciences  Approved 
Savera Cancer and Multispeciality Hospital - Institutional Ethics Committee  Approved 
Shifa Hospital -Institutional Ethics Committee  Approved 
The Institutional Ethics Committee of North East Cancer Hospital and Research Institute   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C01||Malignant neoplasm of base of tongue, (2) ICD-10 Condition: C049||Malignant neoplasm of floor of mouth, unspecified, (3) ICD-10 Condition: C039||Malignant neoplasm of gum, unspecified, (4) ICD-10 Condition: C00||Malignant neoplasm of lip, (5) ICD-10 Condition: C069||Malignant neoplasm of mouth, unspecified, (6) ICD-10 Condition: C02||Malignant neoplasm of other and unspecified parts of tongue, (7) ICD-10 Condition: C059||Malignant neoplasm of palate, unspecified, (8) ICD-10 Condition: C059||Malignant neoplasm of palate, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  A subject will be considered eligible for inclusion in this study only if ALL of the following criteria apply:
1. Subject (or legally acceptable representative) understands and agrees to comply with planned study procedures and provides informed consent prior to initiation of study procedures
2. Male & Female adults ≥18 to < 65 years of age at the time of screening & enrolment.
3. Subject reporting to the site with some kind of oral lesions.

 
 
ExclusionCriteria 
Details  A subject will not be eligible for inclusion in this study if ANY of the following criteria apply:
1. If the subject has participated in another clinical trial in the last 8 weeks before coming at Visit 1.
2. Subject having any other reason which may interfere with the study in the opinion of the Principal Investigator.
3. Subject is blind or falls under the category of vulnerable population. e.g., members of a group with hierarchical structure (e.g. prisoners armed forces personnel, staff and students of medical, nursing and pharmacy academic institutions), patients with incurable diseases, unemployed or impoverished persons, patients in emergency situation, ethnic minority groups, homeless persons, nomads, refugees, minors or other incapable of personally giving consent.
4. If the subject’s mouth does not open wide enough for oral cavity examinations and image acquisition.
5. If according to the judgment of the investigator Subject needs more than 2 biopsy(ies) for assessment after informed consent and oral cavity examination
6. Subjects for whom biopsy(ies) were done for the target lesion(s) more than 60 days from the date of consent.
7. Pregnant or breastfeeding female subjects.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To validate the Artificial Intelligence (AI) algorithm by comparing the output of the algorithm on category of the lesions and the diagnosis of the same images made by investigator capturing the images at the site.  Screening Visit, Visit 1 and Visit 2 
 
Secondary Outcome  
Outcome  TimePoints 
None  None 
 
Target Sample Size   Total Sample Size="3000"
Sample Size from India="3000" 
Final Enrollment numbers achieved (Total)= "3000"
Final Enrollment numbers achieved (India)="3000" 
Phase of Trial   Phase 1/ Phase 2 
Date of First Enrollment (India)   13/05/2022 
Date of Study Completion (India) 30/11/2023 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details
Modification(s)  
None yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Tobacco usage in India is one of the largest preventable cause of non-communicable diseases such as oral cancer, lung cancer, obstructive lung disease and cardiovascular disease, to name a few. Consumption of tobacco in smoked forms (e.g., cigarettes, bidis, cigars, hookah) and smokeless forms (e.g., Gutkha, zarda, khaini) kills nearly a million users annually- all entirely preventable premature deaths.

With nearly 300 million current users of risky tobacco in India, of which 200 million chew smokeless tobacco, the tobacco use epidemic and the resultant deaths from cancers and other preventable diseases are unlikely to abate for the foreseeable future. The effects of smokeless tobacco are most pronounced in the oral cavity, manifesting as submucosal fibrosis, leukoplakia and oral cancers. The incidence of oral cancer in India is among the highest worldwide, comprising nearly half of all oral cancers globally. Already, smokeless tobacco kills more than 350,000 people every year in India. Particularly concerning is the disproportionately higher use of smokeless tobacco among socio-economically disadvantaged groups, women and the rural population. For example, tobacco chewing is common among migrant construction workers, those living in urban slums, truck and metro transport drivers. In the case of pregnant women chewing tobacco, their tobacco use harms them as well as their babies with an increased risk of anaemia, higher rates of stillbirth and lower weight of the newborn.

The user groups of smokeless tobacco often have a poor understanding of tobacco harms and cessation aids, along with poor access to healthcare. Cessation aids in the form of behavioural support and safer nicotine alternatives to smokeless tobacco are not affordable, accessible or available to the majority of the population.

Screening for pre-malignant and early-stage oral cancers can be done by experts by visual inspection. However, if the person at the point of care (POC) who is screening is not skilled and experienced, then the sensitivity and specificity of the visual diagnosis can be very low. This is generally the case in rural healthcare settings. As a result, tobacco user patients from rural and disadvantaged backgrounds are more likely to present late with stage III or stage IV oral cancer. Currently in India, overall survival following treatment at 5 years for Stage I oral cancer is 100% and decreases to 85% for Stage II. For Stages III and IV, 5-year survival can be a mere 43% and 42% respectively. This is further worsened due to lower affordability and access to chemotherapy and radiotherapy for most of the rural populations.

Early screening of pre-cancerous oral lesions such as Leukoplakia and Erythroplakia complemented by opportunistic and comprehensive tobacco cessation support has the potential to be a significant and impactful public health intervention. This is where ORAICLE believes that a well-designed, robustly tested and scientifically validated Artificial Intelligence (AI) algorithm can be a game-changer, and ORAICLE intends to develop an Artificial Intelligence Algorithm that can analyze images of the oral cavity at the POC and categorize the lesions as cancerous or non-cancerous and “red flag” them for further expert evaluation. 

 
Close